Yüksel Ürün/X
Feb 18, 2025, 15:11
Yüksel Ürün: Denosumab every 12 weeks vs. every 4 weeks in mCRPC
Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared a post on X:
“Denosumab every 12 weeks vs. every 4 weeks in mCRPC:
Lower risk of ONJ and tooth infections with q12w dosing.
Favorable long-term safety profile.
Could q12w become the new standard?”
More posts featuring Yüksel Ürün.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 13:29
Feb 21, 2025, 13:07
Feb 21, 2025, 13:06
Feb 21, 2025, 13:03
Feb 21, 2025, 13:00
Feb 21, 2025, 12:53
Feb 21, 2025, 12:41
Feb 21, 2025, 12:39